University at Buffalo - The State University of New York
Skip to Content
Calcium sulfate and platelet-rich plasma make a novel osteoinductive biomaterial for bone regeneration. - PubMed - NCBI
Format

Send to

Choose Destination
See comment in PubMed Commons below
J Transl Med. 2007 Mar 7;5:13.

Calcium sulfate and platelet-rich plasma make a novel osteoinductive biomaterial for bone regeneration.

Author information

1
Department of Oral Biology, University at Buffalo-109 Foster Hall, 3435 Main Street, Buffalo, NY 14214, USA. gintini@buffalo.edu

Abstract

BACKGROUND:

With the present study we introduce a novel and simple biomaterial able to induce regeneration of bone. We theorized that nourishing a bone defect with calcium and with a large amount of activated platelets may initiate a series of biological processes that culminate in bone regeneration. Thus, we engineered CS-Platelet, a biomaterial based on the combination of Calcium Sulfate and Platelet-Rich Plasma in which Calcium Sulfate also acts as an activator of the platelets, therefore avoiding the need to activate the platelets with an agonist.

METHODS:

First, we tested CS-Platelet in heterotopic (muscle) and orthotopic (bone) bone regeneration bioassays. We then utilized CS-Platelet in a variety of dental and craniofacial clinical cases, where regeneration of bone was needed.

RESULTS:

The heterotopic bioassay showed formation of bone within the muscular tissue at the site of the implantation of CS-Platelet. Results of a quantitative orthotopic bioassay based on the rat calvaria critical size defect showed that only CS-Platelet and recombinant human BMP2 were able to induce a significant regeneration of bone. A non-human primate orthotopic bioassay also showed that CS-Platelet is completely resorbable. In all human clinical cases where CS-Platelet was used, a complete bone repair was achieved.

CONCLUSION:

This study showed that CS-Platelet is a novel biomaterial able to induce formation of bone in heterotopic and orthotopic sites, in orthotopic critical size bone defects, and in various clinical situations. The discovery of CS-Platelet may represent a cost-effective breakthrough in bone regenerative therapy and an alternative or an adjuvant to the current treatments.

PMID:
17343737
PMCID:
PMC1831762
DOI:
10.1186/1479-5876-5-13
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center